Abstract
PMEPA1 gene isoforms to indicate disease progression in solid tumors.
Author
Shashwat Sharad
Center for Prostate Disease Research, Department of Surgery, USUHS, Bethesda, MD
info_outline
Shashwat Sharad, Zsã³fia Sztupinszki, Zoltan Szallasi, Inger L. Rosner, Shiv Srivastava, Albert Dobi, Jennifer Cullen, Hua Li
Full text
Authors
Shashwat Sharad
Center for Prostate Disease Research, Department of Surgery, USUHS, Bethesda, MD
info_outline
Shashwat Sharad, Zsã³fia Sztupinszki, Zoltan Szallasi, Inger L. Rosner, Shiv Srivastava, Albert Dobi, Jennifer Cullen, Hua Li
Organizations
Center for Prostate Disease Research, Department of Surgery, USUHS, Bethesda, MD, Department of Bio and Health Informatics, Technical University of Denmark, Lyngby, Denmark, Harvard Medical School, Boston, MA, Center for Prostate Disease Research, Bethesda, MD, Centre for Prostatic Disease Research, Rockville, MD
Abstract Disclosures
Research Funding
Other
Background:
Dysfuncitons of androgen and TGF-β signaling play important roles in prostate tumorigenesis.
PMEPA1
gene has been defined as an androgen and TGF-β responsive gene which inhibits androgen and TGF-β signaling via negative feed-back loops. Our previous data has established that
PMEPA1
distinct isoforms (
PMEPA1-a
and
PMEPA1-b
) with disparities within N-terminus protein sequences navigate different androgen/TGF-β signaling regulations. In this study, the roles of
PMEPA1
isoforms in disease progressions were investigated in solid tumors of prostate (CaP), breast, lung and colon.
Methods:
RNA seq data from total 2479 solid tumor samples in the TCGA dataset were used to study the correlation between expressions of
PMEPA1
isoforms and disease progression including Gleason score, pathology stages, progression free survival rate (PFS) and overall survival rate (OS). The cohort is composed of 482 prostate, 1049 breast, 499 lung and 449 colon cancer patients.
Results:
In CaP, the TCGA data analysis showed that lower transcript level of
PMEPA1-b
isoform associated with higher Gleason scores and lower progression free survival rate (PFS) (P = 0.014) and worse overall survival rate (OS) (P < 0.01). The ratio of mRNA levels of
PMEPA1-a
versus
PMEPA-b
indicated higher Gleason score, lower PFS rate (P = 0.0063) and worse OS rate (P = 0.0042). In contrast, higher expression of both
PMEPA1-a
and PMEPA-
b
associated with lower PFS (P = 0.023 and 0.028, respectively) in breast cancer. And the enhanced ratio of
PMEPA1-a
/
b
was also found to indicate lower PFS (P = 0.016) and worse OS (P = 0.016) in breast cancer. Similarly, the increased transcript levels of
PMEPA1-a
and
PMEPA1-b
isoforms significantly associated with lower PFS and worse OS rates in lung and colon cancer. The expression of
PMEPA1
isoforms was not found to associate with pathology stages of diseases.
Conclusions:
Our data establish the biomarker potential of
PMEPA1
gene isoforms (
a
and
b
) indicating more aggressive disease progressions in 4 solid tumors, further underscoring the
PMEPA1
isoform specific biological functions to differentiate regulation of androgen and TGF-β signaling in cancer cells.